Today, Qlife has signed an agreement to terminate a long-term lease for its high-tech laboratory and office facility in Ballerup. The termination of the lease will reduce Qlife’s annual rent & facility cost by 7.3 MSEK as of November 1st 2023
Since the start of 2023, Qlife has continuously scaled down on costs, workforce and operates mainly by outsourcing. The termination of the lease is part of Qlife’s new operation model to implement additional cost savings.
“Qlife will step out of its long term lease for high-tech facilities to implement the last significant cost reduction measure in the execution of our new operation model. The cancellation of the long-term lease will have a significant financial effect on the company and our ability to reach our long-term objectives”, says Thomas Warthoe, CEO of Qlife.
Qlife will remain operating from scaled down office- and lab-facilities at Industriparken in Ballerup through a short term sublease with the new main lease holder.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today’s view on healthcare into tomorrow’s focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health – so that they can move beyond reactive care towards proactive wellbeing. It’s how we contribute to improving quality of life for every individual and for the greater society.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.